Secondary analysis of FINEARTS-HF in HF with mildly reduced or preserved EF: finerenone's effect on total HF events and CV death vs placebo did not significantly differ by baseline eGFR (rate ratio 0.72, 0.83, 1.02 across categories) or UACR.
Secondary analysis
Mc Causland et al. Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial